Table 4. Univariate analysis for factors predicting omental metastasis in the upfront surgery group.

Variables	N  = 114	Omental metastasis negative ( n  = 100)	Omental metastasis positive ( n  = 14)	p -Value
Age (y)	55.75 ± 12.38	55.99 ± 12.40	54.0 ± 12.55	0.576
Sex
Male	79 (69.3%)	71 (71.0%)	8 (57.1%)	0.356
Female	35 (30.7%)	29 (29.0%)	6 (42.9%)
Clinical “T” stage
cT1 + cT2	20 (17.5%)	20 (20.0%)	0 (0.0)	0.001
cT3	31 (27.2%)	31 (31.0%)	0 (0.0)
cT4	63 (55.3%)	49 (49.0%)	14 (100%)
Pathological “T” stage
pT0 + pT1 + pT2	20 (17.5%)	20 (20.0%)	0 (0.0)	0.001
pT3	31 (27.2%)	31 (31.0%)	0 (0.0)
pT4	63 (55.3%)	49 (49.0%)	14 (100.0%)
Pathological “N” stage
pN0	27 (23.7%)	27 (27.0%)	0 (0.0)	0.038
pN+	87 (76.3%)	73 (73.0%)	14 (100%)
Subtotal vs total gastrectomy
Subtotal	85 (74.6%)	75 (75.0%)	10 (71.4%)	0.751
Total	29 (25.4%)	25 (25.0%)	4 (28.6%)
Greater curvature tumors
No	42 (36.8%)	38 (38.0%)	4 (28.6%)	0.493
Yes	72 (63.2%)	62 (62.0%)	10 (71.4%)
Tumor size (cm)	4 (3–6)	3.95 (3–5.6)	6 (4.9–8)	0.002
Tumor depth (cm)	1.22 ± 0.60	1.17 ± 0.60	1.57 ± 0.69	0.019
Lymphovascular invasion
No	79 (69.3%)	70 (70.0%)	9 (64.3%)	0.759
Yes	35 (30.7%)	30 (30.0%)	5 (35.7%)
Perineural invasion
No	96 (84.2%)	88 (88.0%)	8 (57.1%)	0.009
Yes	18 (15.8%)	12 (12.0%)	6 (42.9%)
Perinodal extension
No	40 (35.1%)	38 (38.0%)	2 (14.3%)	0.133
Yes	74 (64.9%)	62 (62.0%)	12 (85.7%)
Signet ring cell tumor
Yes	5 (4.4%)	4 (4.0%)	1 (7.1%)	0.487
No	109 (95.6%)	96 (6.0%)	13 (92.9%)
Histological grade of the tumor
Well to moderately differentiated	47 (41.2%)	59 (59.0%)	10 (71.4%)	0.537
Poorly differentiated	67 (58.8%)	41 (41.0%)	4 (28.6%)
Recurrence
No	76 (66.7%)	72 (72.0%)	4 (28.6%)	0.002
Yes	38 (33.3%)	28 (28.0%)	10 (71.4%)

Note: Values expressed as n (%) or mean ± SD or median (range).